EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.68
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$33.83

21 Nov
2024

-0.070

OPEN

$33.52

-0.21%

HIGH

$34.00

43,840

LOW

$33.41

TARGET
$35.18 4.0% upside
Franking for last dividend paid out: 49%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 141.3 138.3 xxx
DPS (cps) xxx N/A 97.5 xxx
EPS Growth xxx 6.3% - 2.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 24.4 xxx
Dividend Yield xxx N/A 2.9% xxx
Div Pay Ratio(%) xxx N/A 70.5% xxx

Dividend yield today if purchased 3 years ago: 1.57%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.63

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/08 - ex-div 49.71c (franking 49%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx141.3
DPS All xxxxxxxxxxxxxxx114.5
Sales/Revenue xxxxxxxxxxxxxxx13,189.1 M
Book Value Per Share xxxxxxxxxxxxxxx1,268.4
Net Operating Cash Flow xxxxxxxxxxxxxxx348.2 M
Net Profit Margin xxxxxxxxxxxxxxx2.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx11.12 %
Return on Invested Capital xxxxxxxxxxxxxxx7.88 %
Return on Assets xxxxxxxxxxxxxxx4.12 %
Return on Equity xxxxxxxxxxxxxxx11.12 %
Return on Total Capital xxxxxxxxxxxxxxx12.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx96.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx823 M
Long Term Debt xxxxxxxxxxxxxxx820 M
Total Debt xxxxxxxxxxxxxxx1,643 M
Goodwill - Gross xxxxxxxxxxxxxxx2,068 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx217 M
Price To Book Value xxxxxxxxxxxxxxx2.32

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx118.8 M
Capex % of Sales xxxxxxxxxxxxxxx0.90 %
Cost of Goods Sold xxxxxxxxxxxxxxx12,232 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx474 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx89 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.8

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

22/08/2024

3

Neutral

$33.00

-2.45%

Ebos Group reported an in-line FY24 result, while FY25 earnings guidance is -2% lower than consensus at the mid-point. Citi views the mid-point of guidance as achievable, calculating it implies 5% organic top-line growth.

The unwinding of the Chemist Warehouse contract will be an -$80m headwind to earnings, Citi notes, partially offset by cost efficiencies and organic growth. Upside risks to guidance include M&A and a better consumer environment, especially for Animal Care.

Neutral retained, target rises to $33.00 from $31.50.

FORECAST
Citi forecasts a full year FY25 dividend of 101.00 cents and EPS of 140.00 cents.
Citi forecasts a full year FY26 dividend of 111.00 cents and EPS of 158.00 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

27/08/2024

3

Downgrade to Neutral from Overweight

-

-

Ebos Group posted a solid result in line with Jarden's expectations of underlying earnings up 7% year on year. The dividend was up 9% on a 70% payout ratio.

FY25 maiden earnings guidance of $575-600m compares to Jarden's forecast of $601m, the decline mostly reflecting the impact of non-renewal of the Chemist Warehouse contract, which generated revenues of $2.2bn.

Key drivers include base business growth across both divisions, Community Pharmacy revenue and share growth and cost initiatives.

With Ebos' share price now better capturing earnings prospects and potential bolt-on M&A activity, Jarden downgrades to Neutral from Overweight on more limited valuation upside. Target unchanged at NZ$38.

FORECAST
Jarden forecasts a full year FY25 dividend of 112.00 cents and EPS of 144.00 cents.
Jarden forecasts a full year FY26 dividend of 114.00 cents and EPS of 163.00 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
In Case You Missed It – BC Extra Upgrades & Downgrades – 30-08-24

Aug 30 2024 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Aug 27, 2024

Aug 27 2024 - Daily Market Reports
3
FNArena Corporate Results Monitor – 22-08-2024

Aug 22 2024 - Australia
4
Rudi’s View: How To Invest Allan’s $300k, Part 2

Jul 25 2024 - Rudi's View
5
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia